Researchmoz added Most up-to-date research on "Navelbine (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020" to its huge collection of research reports.
GlobalDatas pharmaceuticals report, Navelbine (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Comtan sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Non-Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Navelbine including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Navelbine including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Navelbine in each of the seven major markets
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=28368
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drugs performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content
1 Table of contents 21.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Pipeline Report Guidance 8
3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11
4 TNM Classification of NSCLC 12
5 Navelbine 155.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Navelbine 16
5.5 Factors Affecting Sales of Navelbine 17
5.5.1 Oral Administration 17
5.5.2 Combination with Cisplatin 17
5.5.3 Patent Expiry 17
5.6 Drug Risk Benefit Score 17
5.6.1 Efficacy 17
5.6.2 Safety 18
5.6.3 Compliance 18
5.6.4 Dosing Convenience 18
5.7 Intensity of Competition 18
5.8 Sales forecast 18
5.8.1 Target patient Pool of Navelbine 18
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of Navelbine 20
6 NSCLC Market: Appendix 29
6.1 Market Definitions 29
6.2 Abbreviations 29
6.3 Research Methodology 29
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 33
6.5 Disclaimer 33
6.6 Sources 33
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=28368
GlobalDatas pharmaceuticals report, Navelbine (Non Small Cell Lung Cancer)-Analysis and Forecasts to 2020 provides Comtan sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Non-Small Cell Lung Cancer market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Navelbine including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Navelbine including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2011-2020 for Navelbine in each of the seven major markets
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=28368
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drugs performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content
1 Table of contents 21.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 NSCLC Market 4
2.2 Epidemiology 4
2.3 Etiology 6
2.3.1 Tobacco 6
2.3.2 Radon 6
2.3.3 Asbestos 6
2.3.4 Other Environmental Agents 7
2.4 GlobalData Pipeline Report Guidance 8
3 NSCLC Disease: Market Characterization 9
3.1 NSCLC Disease Market 9
3.2 NSCLC Disease Market Forecasts and CAGR 9
3.3 Drivers for the NSCLC Disease Market 9
3.3.1 High Incidence 10
3.3.2 High Mortality Rate 11
3.3.3 Increased Use of Chemotherapy in Early Stages of NSCLC 11
3.3.4 Emergence of Targeted Drugs and Maintenance Therapy 11
3.3.5 Promising Pipeline Drugs 11
4 TNM Classification of NSCLC 12
5 Navelbine 155.1 Introduction 15
5.2 Mechanism of Action 15
5.3 Clinical Studies 15
5.4 Approval History of Navelbine 16
5.5 Factors Affecting Sales of Navelbine 17
5.5.1 Oral Administration 17
5.5.2 Combination with Cisplatin 17
5.5.3 Patent Expiry 17
5.6 Drug Risk Benefit Score 17
5.6.1 Efficacy 17
5.6.2 Safety 18
5.6.3 Compliance 18
5.6.4 Dosing Convenience 18
5.7 Intensity of Competition 18
5.8 Sales forecast 18
5.8.1 Target patient Pool of Navelbine 18
5.8.2 Dosing 19
5.8.3 Market Penetration 19
5.8.4 Annual Cost of Therapy 19
5.8.5 Sales Projections of Navelbine 20
6 NSCLC Market: Appendix 29
6.1 Market Definitions 29
6.2 Abbreviations 29
6.3 Research Methodology 29
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 33
6.5 Disclaimer 33
6.6 Sources 33
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=28368
No comments:
Post a Comment